Serum Intestinal Fatty Acid Binding Protein in Patients with Small Bowel Obstruction
- 1 Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- 2 Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- 3 Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- 4 DS Pharma Biomedical Co., Ltd., Osaka, Japan
- 5 Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- 6 Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- 7 Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Abstract
Purpose: The aims of this pilot study were to reveal the biological characteristics of serum I-FABP and explore its clinical utility as a biomarker in patients with small bowel obstruction (SBO). Methods: Serum I-FABP levels were measured in 37 consecutive patients with SBO between 2007 and 2008. Serum I-FABP levels were compared between ischemia (n = 10) and non-ischemia (n = 27) groups. Serum I-FABP levels were longitudinally analyzed in 21 patients who showed high (>2.0 ng/ml) serum I-FABP levels. The relationship between serum I-FABP level and length of damaged bowel was also analyzed. Results: Median serum I-FABP levels were 9.2 ng/ml in the ischemia group and 1.9 ng/ml in the non-ischemia group (p < 0.0001). The elevated I-FABP levels rapidly decreased after therapeutic intervention and normalized on the third day in all patients. Linear regression analysis revealed a positive correlation between I-FABP levels and lengths of surgically excised bowels (y = 2.527x － 7.660, r = 0.604, p = 0.0018). By setting the cutoff level at 7.2 ng/ml, the diagnostic ability of serum I-FABP was 70.0% in terms of sensitivity, 92.6% in terms of specificity, and 86.5% in terms of accuracy. Conclusion: Serum I-FABP sensitively reflects bowel damage in SBO patients and seems to be a potential biomarker for detecting small-bowel ischemia.
- D. Hashimoto, M. Hirota, T. Matsukawa, Y. Yagi and Baba H, “Clinical Features of Strangulated Small Bowel Obstruction,” Surgery Today, Vol. 42, No. 11, 2012, pp. 1061-1065. doi:10.1007/s00595-012-0207-8
- M. Assenza, G. Ricci, V. Macciucca-Mde, E. Polettini, E. Casciani, M. L. De Cicco, et al., “Comparison among Preoperative Single-slice CT and Multi-Slice CT in Simple, Closed Loop and Strangulating Bowel Obstruction,” Hepatogastroenterology, Vol. 54, No. 79, 2007, pp. 2017-2023.
- K. Kato, K. Mizunuma, M. Sugiyama, S. Sugawara, T. Suzuki, M. Tomabechi, et al., “Interobserver Agreement on the Diagnosis of Bowel Ischemia: Assessment Using Dynamic Computed Tomography of Small Bowel Obstruction,” Japanese Journal of Radiology, Vol. 28, No. 10, 2010, pp. 727-732. doi:10.1007/s11604-010-0500-7
- A. Blachar, S. Barnes, S. Z. Adam, G. Levy, I. Weinstein, R. Precel, et al., “Radiologists’ Performance in the Diagnosis of Acute Intestinal Ischemia, Using MDCT and Specific CT Findings, Using a Variety of CT Protocols,” Emergency Radiology, Vol. 18, No. 5, 2011, pp. 385-394. doi:10.1007/s10140-011-0965-4
- N. J. Evennett, M. S. Petrov, A. Mittal and J. A. Windsor, “Systematic Review and Pooled Estimates for the Diagnostic Accuracy of Serological Markers for Intestinal Ischemia,” World Journal of Surgery, Vol. 33, No. 7, 2009, pp. 1374-1383. doi:10.1007/s00268-009-0074-7
- D. H. Alpers, A. W. Strauss, R. K. Ockner, N. M. Bass and J. I. Gordon, “Cloning of a cDNA Encoding Rat Intestinal Fatty Acid-Binding Protein,” Proceedings of the National Academy of Sciences of the United of America, Vol. 81, No. 2, 1984, pp. 313-317. doi:10.1073/pnas.81.2.313
- L. B. Agellon, M. J. Toth and A. B. Thomson, “Intracellular Lipid Binding Proteins of the Small Intestine,” Molecular and Cellular Biochemistry, Vol. 239, No. 1-2, 2002, pp. 79-82. doi:10.1023/A:1020520521025
- M. N. Pelsers, Z. Namiot, W. Kisielewski, A. Namiot, M. Januszkiewicz, W. T. Hermens, et al., “Intestinal-Type and Liver-Type Fatty Acid-binding Protein in the Intestine. Tissue Distribution and Clinical Utility,” Clinical Biochemistry, Vol. 36, No. 7, 2003, pp. 529-535. doi:10.1016/S0009-9120(03)00096-1
- T. Kanda, Y. Nakatomi, H. Ishikawa, M. Hitomi, Y. Matsubara, T. Ono, et al., “Intestinal Fatty Acid-Binding Protein as a Sensitive Marker of Intestinal Ischemia,” Digestive Diseases and Sciences, Vol. 37, No. 9, 1992, pp. 1362-1367. doi:10.1007/BF01296004
- T. Kanda, T. H. Fujii, M. Fujita, Y. Sakai, T. Ono and K. Hatakeyama, “Intestinal Fatty Acid-Binding Protein is Available for Diagnosis of Intestinal Ischaemia: Immunochemical Analysis of Two Patients with Ischaemic Intestinal Diseases,” Gut, Vol. 36, No. 5, 1995, pp. 788-791. doi:10.1136/gu t.36.5.788